Canada approves Novavax’s COVID-19 vaccine
Canada approves Novavax’s COVID-19 vaccine

Canada approves Novavax’s COVID-19 vaccine

Vial marked “VACCINE Coronavirus COVID-19” and a syringe are shown in front of a certain Novavax logo in this illustration taken on December 11, 2021. REUTERS / Dado Ruvic

Sign up now for FREE unlimited access to Reuters.com

February 17 (Reuters) – Canada’s health regulator said on Thursday it had approved Novavax’s (NVAX.O) COVID-19 vaccine for use in people aged 18 years and older.

The safety and efficacy of the vaccine in people under the age of 18 have not yet been established, Health Canada said in its release.

Canada has committed to purchase 52 million doses of the vaccine with the option to purchase up to 24 million more doses.

Novavax’s protein-based vaccine is being reviewed by the US Food and Drug Administration and has received approvals from the EU and the World Health Organization.

It has also been approved for use in adults in countries including the UK, New Zealand and Australia. The company said last week that its vaccine was about 80% effective at a late stage of trials in adolescents.

Sign up now for FREE unlimited access to Reuters.com

Reporting of Mrinalika Roy in Bengaluru; Editing Devika Syamnath

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.